Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis

Carbone, Marco; Invernizzi, Pietro

doi:10.1002/cld.587

Clinical Liver Disease

2016

DOI: 10.1002/cld.587

|View full text |Cite

Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis

Marco Carbone

Pietro Invernizzi

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/8-5-reading-invernizzi.html a video presentation of this article https://www.wileyhealthlearning.com/Activity/4679249/disclaimerspopup.aspx questions and earn CME

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Investigational drugs in phase II clinical trials for primary biliary cholangitis

Silveira

Lindor

2017

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that may lead to biliary fibrosis, and eventually cirrhosis. The primary treatment for PBC is ursodeoxycholic acid (UDCA), which has favorably altered its natural history. However, up to 40% of patients have an inadequate response to UDCA, and are therefore at high risk of liver-related complications. Obeticholic acid has recently been approved for use in patients with PBC with inadequate response or who are intolerant to UDCA, but improvement in long-term outcomes has not yet been demonstrated. Alternative therapeutic options for PBC are needed. Areas covered: Recent advances in research including epidemiological, genetic and pre-clinical studies in animal models of PBC have yielded numerous agents currently at different stages of development for treatment of patients with PBC; in this review, we cover novel therapies that were recently or are recently being investigated in phase II clinical trials. Expert opinion: Despite the evolving landscape in PBC, the main challenges facing development of novel therapies remain the rarity of the disease and the limitations to design and conduct of controlled clinical trials in PBC, which are needed to determine the long-term effects of novel therapies on the clinical outcomes of PBC.

show abstract

Investigational drugs in phase II clinical trials for primary biliary cholangitis

Silveira

Lindor

2017

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/8-5-reading-invernizzi.html a video presentation of this article https://www.wileyhealthlearning.com/Activity/4679249/disclaimerspopup.aspx questions and earn CME

Cited by 1 publication

References 22 publications

Investigational drugs in phase II clinical trials for primary biliary cholangitis

Investigational drugs in phase II clinical trials for primary biliary cholangitis

Contact Info

Product

Resources

About